AEZS
Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel(R)
Monday 10/27/2014 07:30 AM ET - PR Newswire via Dow Jones News
QUÉBEC CITY, Oct. 27, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company") today announced the formal implementation of its own full-time U.S. sales force with field selling of ASCEND Therapeutics US LLC(') s ("ASCEND"), EstroGel(R) , scheduled to start the week of November 17, 2014. EstroGel(R) is the leading non-patch transdermal brand of estrogen replacement therapy commercialized in the U.S. The selling of EstroGel(R) by Aeterna Zentaris is part of the strategic co-promotion services agreement signed last August with ASCEND which stipulates that Aeterna Zentaris will market this product, in specific U.S. territories. For its part, ASCEND would market, in specific U.S. territories, Aeterna Zentaris' product, Macrilen(TM), for use in the evaluation of adult growth-hormone deficiency ("AGHD"). A New Drug Application ("NDA") for Macrilen is currently under review by the FDA, with a Prescription Drug User Fee Act ("PDUFA") date of November 5, 2014. In consideration for these co-promotion services, each party will be entitled to receive, from the other party, commissions on net sales of each other's product.
